

L11 ANSWER 8 OF 29 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 1
ACCESSION NUMBER: 2003:799397 CAPLUS
DOCUMENT NUMBER: 139:336696
TITLE: Treatment of chronic **graft-versus-host** disease with **anti-CD20**
chimeric monoclonal antibody
AUTHOR(S): Ratanatharathorn, Voravit; Ayash, Lois; Reynolds,
Christopher; Silver, Samuel; Reddy, Pavan; Becker,
Michael; Ferrara, James L. M.; Uberti, Joseph P.
CORPORATE SOURCE: Blood and Marrow Stem Cell Transplantation Program,
University of Michigan Health System, Ann Arbor, MI,
USA
SOURCE:  Biology of Blood and Marrow Transplantation (2003),
9(8), 505-511
CODEN: BBMTF6; ISSN: 1083-8791
PUBLISHER: Elsevier Science
DOCUMENT TYPE: Journal
LANGUAGE: English
AB We reviewed the clin. outcome of 8 patients with steroid-refractory
chronic graft-vs.-host disease (GVHD) who received an anti-CD20 chimeric
monoclonal antibody (rituximab). Rituximab was given by i.v. infusion at
a weekly dose of 375 mg/m² for 4 wk. All patients had received extensive
treatment with various immunosuppressive agents; 6 patients had also
received extracorporeal photopheresis. All patients had extensive chronic
GVHD with diffuse or localized sclerodermod GVHD and xerophthalmia.
Other extracutaneous involvements included cold agglutinin disease with
the Raynaud phenomenon, membranous glomerulonephritis, and restrictive or
obstructive lung disease. Four patients responded to treatment with
ongoing resoln. or improvement ranging from 265 to 846 days after therapy,
despite recovery of B cells in 3 patients. Rituximab seems to have
significant activity in the treatment of refractory chronic GVHD and
should be considered for further study in patients with early disease.
This study suggests a participating role of B cells in the pathogenesis of
chronic GVHD.
REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 9 OF 29 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
ACCESSION NUMBER: 2003:328548 SCISEARCH
THE GENUINE ARTICLE: 662VH
TITLE: **Anti-CD20** monoclonal antibody in the
treatment of patients with refractory chronic
graft versus host disease
AUTHOR: Stamatovic D (Reprint); Tukic L; Tarabar O; Simic L;
Malesevic M
SOURCE: BONE MARROW TRANSPLANTATION, (MAR 2003) Vol. 31, Supp.
[1], pp. S131-S131.
Publisher: NATURE PUBLISHING GROUP, MACMILLAN BUILDING, 4
CRINAN ST, LONDON N1 9XW, ENGLAND.
ISSN: 0268-3369.
DOCUMENT TYPE: Conference; Journal
LANGUAGE: English
REFERENCE COUNT: 0

L11 ANSWER 10 OF 29 USPATFULL on STN
ACCESSION NUMBER: 2002:47987 USPATFULL
TITLE: Treatment of B cell malignancies using combination of B
cell depleting antibody and immune modulating antibody
related applications
INVENTOR(S): Hanna, Nabil, Rancho Santa Fe, CA, UNITED STATES
Hariharan, Kandasamy, San Diego, CA, UNITED STATES

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION:
APPLICATION INFO.:

US 2002028178 A1 20020307
US 2001-855717 A1 20010516 (9)

NUMBER DATE

PRIORITY INFORMATION: US 2000-217706P 20000712 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Pillsbury Winthrop LLP, Intellectual Property Group,
East Tower, Ninth Floor, 1100 New York Avenue, N.W.,
Washington, DC, 20005-3918

NUMBER OF CLAIMS: 103

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 6 Drawing Page(s)

LINE COUNT: 3047

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A combination antibody therapy for treating B cell malignancies using an immunoregulatory antibody, especially an anti-B7, anti-CD23, or anti-CD40L antibody and a B cell depleting antibody, especially anti-CD19, anti-CD20, anti-CD22 or anti-CD37 antibody is provided. Preferably, the combination therapy will comprise anti-B7 and anti-CD20 antibody administration.

=>